Nicotine promotes vascular calcification via intracellular Ca$^{2+}$-mediated, Nox5-induced oxidative stress, and extracellular vesicle release in vascular smooth muscle cells

Ploingarm Petsophonsakul $^{1}$$^{1t}$, Mathias Burgmaier $^{1,2}$$^{†}$, Brecht Willems $^{1}$, Sylvia Heeneman $^{3}$, Nadina Stadler $^{3}$$^{†}$, Felix Gremse $^{4}$, Sebastian Reith $^{5}$, Kathrin Burgmaier $^{6}$, Florian Kahles $^{2}$, Nikolaus Marx $^{2}$$^{†}$, Ehsan Natour $^{7,8}$, Elham Bidar $^{7,8}$, Michael Jacobs $^{8,9}$, Barend Mees $^{8,9}$, Chris Reutelingsperger $^{1}$$^{†}$, Malgorzata Furmanik $^{1}$, and Leon Schurgers $^{1,10}$$^{*}$

$^{1}$Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands; $^{2}$Department of Cardiology, Medical Clinic I, University Hospital of the RWTH Aachen, Aachen, Germany; $^{3}$Department of Pathology, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands; $^{4}$Experimental Molecular Imaging, University Hospital of the RWTH Aachen, Aachen, Germany; $^{5}$Department of Cardiology, St. Frarazius Hospital Münster, Münster, Germany; $^{6}$Department of Pediatrics, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany; $^{7}$Department of Cardiovascular Surgery, Maastricht University Medical Center (MUMC), Maastricht, The Netherlands; $^{8}$Department of Vascular Surgery, European Vascular Center Aachen-Maastricht, Maastricht, The Netherlands; $^{9}$Department of Vascular Surgery, Maastricht University Medical Center (MUMC), Maastricht, The Netherlands; and $^{10}$Institute of Experimental Medicine and Systems Biology, RWTH Aachen University, Aachen, Germany

Received 17 June 2020; editorial decision 8 July 2021; accepted 15 July 2021; online publish-ahead-of-print 17 July 2021

Aims

Smokers are at increased risk of cardiovascular events. However, the exact mechanisms through which smoking influences cardiovascular disease resulting in accelerated atherosclerosis and vascular calcification are unknown. The aim of this study was to investigate effects of nicotine on initiation of vascular smooth muscle cell (VSMC) calcification and to elucidate underlying mechanisms.

Methods and results

We assessed vascular calcification of 62 carotid lesions of both smoking and non-smoking patients using ex vivo microcomputed tomography ($\mu$CT) scanning. Calcification was present more often in carotid plaques of smokers ($n = 22$ of $30$, $73.3\%$) compared to non-smokers ($n = 11$ of $32$, $34.3\%$; $P < 0.001$), confirming higher atherosclerotic burden. The difference was particularly profound for microcalcifications, which was $17$-fold higher in smokers compared to non-smokers. In vitro, nicotine-induced human primary VSMC calcification, and increased osteogenic gene expression (Runx2, Osx, BSP, and OPN) and extracellular vesicle (EV) secretion. The pro-calcifying effects of nicotine were mediated by Ca$^{2+}$-dependent Nox5. SiRNA knock-down of Nox5 inhibited nicotine-induced EV release and calcification. Moreover, pre-treatment of hVSMCs with vitamin K2 ameliorated nicotine-induced intracellular oxidative stress, EV secretion, and calcification. Using nicotinic acetylcholine receptor (nAChR) blockers $\alpha$-bungarotoxin and hexamethonium bromide, we found that the effects of nicotine on intracellular Ca$^{2+}$ and oxidative stress were mediated by $\alpha_7$ and $\alpha_3$ nAChR. Finally, we showed that Nox5 expression was higher in carotid arteries of smokers and correlated with calcification levels in these vessels.

Conclusion

In this study, we provide evidence that nicotine induces Nox5-mediated pro-calcific processes as novel mechanism of increased atherosclerotic calcification. We identified that activation of $\alpha_7$ and $\alpha_3$ nAChR by nicotine increases intracellular Ca$^{2+}$ and initiates calcification of hVSMCs through increased Nox5 activity, leading to oxidative stress-mediated EV release. Identifying the role of Nox5-induced oxidative stress opens novel avenues for diagnosis and treatment of smoking-induced cardiovascular disease.

* Corresponding author. Tel: +31 43 3881680; fax: +31 43 388 4159; E-mail: l.schurgers@maastrichtuniversity.nl
† These authors contributed equally to this work.
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
1. Introduction

Cigarette smoking is a major cause of coronary heart disease and cardiovascular diseases (CVDs). According to the 2014 Surgeon General’s Report on smoking and health, smoking is responsible for approximately one of every four deaths from CVD. Smoking has been shown to be associated with increased cardiovascular morbidity and mortality in a dose-dependent manner. Because of its detrimental effect, smoking remains the most important modifiable risk factor for CVD outcome.

Vascular calcification is a strong and independent risk factor of CVD and used as a parameter to detect atherosclerotic burden in patients. Vascular calcification is the deposition of hydroxyapatite crystals in the vasculature which can be categorized by size. Microcalcification is an active dynamic process caused by vesicle-mediated mineralization, apoptotic bodies, and osteogenic differentiation. It precedes macrocalcification and is considered detrimental. Vascular calcification is commonly observed in atherosclerosis, aortic aneurysm, chronic kidney disease, and diabetes. Arterial intimal calcification is associated with arterial obstruction and atherosclerotic plaque rupture, whereas arterial medial calcification is associated with arterial stiffness, systolic hypertension, and aortic aneurysm. Vascular calcification is an active process driven by vascular smooth muscle cells (VSMCs), which are the major cell type in the vessel wall and are located in the tunica media. Vascular calcification arises from differentiation of VSMC, VSMC apoptosis, and mineralization of extracellular vesicles (EVs). Lineage-tracing studies reveal that VSMCs undergo phenotypic switching and give rise to a variety of cells, including osteogenic-like cells, which contribute to vascular calcification. Thus, VSMCs are well recognized as key player in atherogenesis and atherosclerotic plaque calcification.

Cigarette smoking is strongly associated with (sub-)clinical atherosclerosis including coronary artery, peripheral artery, and aortic calcification. A growing body of evidence suggests that nicotine, a major constituent of cigarette smoke, accounts for impaired vascular function and vascular calcification. In this study, we aimed to unravel the mechanistic link between nicotine- and VSMC-indu ed vascular calcification. We investigate the effect of smoking on calcification in human carotid plaques and explore the effect of nicotine on VSMC processes that lead to vascular calcification in vitro.

2. Methods

2.1 Quantification of microcalcifications in patients

Human carotid artery lesion specimen from 30 patients, previously collected during autopsies at the University Hospital Maastricht, Maastricht, the Netherlands, via the Maastricht Pathology Tissue Collection, was used. The collection, storage, and processing of tissue and patient data are in accordance with the ‘Code for Proper Use of Secondary Human Tissue in the Netherlands’ and conform to the principles outlined in the Declaration of Helsinki. Micro-computed tomography (µCT) images were captured using a µCT scanner (Tomoscope DUO, CT-Imaging, Erlangen, Germany). Sources of the µCT were operated with voltage of 65 kV and current of 0.5 mA. About 720 projections with 1032 x 1012 pixels were acquired during one revolution with duration of 90 seconds. Volumetric images were reconstructed using a Feldkamp Reconstruction at voxel size 35 μm using a medium sharp reconstruction kernel (T60). Volumetric images were visualized and analysed using the Imalytics.
Preclinical Software. Califications were interactively segmented and counted using a fixed threshold (100 HU) and connected component analysis. In order to show differences in calcification according to calcification size, segmented components were grouped into small, medium, and large classes based on their volumes (< 0.01 mm³, < 0.1 mm³, and > 0.1 mm³). Due to the lack of previous studies using this design and set-up, these cut-offs were chosen based on the scanners resolution, specimen size, and distribution of calcification size. Volumes were determined based on the segmentation size, that is proportional to the number of segmented voxels. Calcification amount per voxel was assumed to be proportional to the voxel intensity, and the amount of calcification per plaque was computed as the sum of the corresponding voxels.

2.2 VSMC culture and treatments

Human primary VSMCs were isolated from a non-diseased region of aortic tissue obtained from patients undergoing aortic aneurysm surgical repair. Tissue was considered as a waste material from the Vascular Surgery Unit of University Hospital Maastricht, Maastricht, the Netherlands, and University Hospital RWTH Aachen, Aachen, Germany. The collection, storage, and processing of tissue and patient data are in accordance with the ‘Code for Proper Use of Secondary Human Tissue in the Netherlands’, the Ethics Committee of the Faculty of Medicine, University Hospital RWTH Aachen, and the Declaration of Helsinki. VSMCs were cultured in DMEM (Gibco) supplemented with 20% FBS (Gibco) and 1% penicillin/streptomycin (PS) (Gibco). VSMCs were passaged when 90% confluent and used for experiments at passage 3–10. VSMCs were stimulated with nicotine (150 nM, 1 μM, 1 mM, 5 mM, 10 mM, Sigma, N3876) or vehicle control (ethanol). Inhibitor treatments were carried out prior to nicotine stimulation: GKT136901 (1 μM, 5 μM, Cayman chemical, 17764), α-bungarotoxin (1 μM, 10 μM, Life Technologies, B1601), N-acetyl-cysteine (0.5 μM, Sigma, A7250), Vitamin K (Menadione-7, 10 μM, Nattopharma ASA), Stattic (1 μM, Abcam, ab120952), SU6656-SrcFK inhibitor (2 μM, Sigma, S9692), GS26565157-PERK inhibitor (2 μM, ApexBio, B2175), and BPAT-AM (1 μM, Molecular probes #d1207). SiRNA transfection (Nox5: S103243856, Qiagen; p22phox: L-011020-02-0005, Horizon Discovery) was carried out using the Neon Transfection System (Thermo Fisher Scientific) and kit following the manufacturer’s protocol for human aortic smooth muscle cells.

2.3 Statistical analysis

Data are shown as mean ± SD and were obtained in three or more independent experiments. Normality of all data was tested using the Shapiro–Wilks test. If data were not normally distributed, Mann–Whitney and Kruskal–Wallis tests were used; otherwise, statistical significance was tested with t-test, one-sample test, and one-way ANOVA with Bonferroni post hoc for experiments with two and more groups, respectively. Statistical analysis was carried out using GraphPad Prism 8.2.0. All clinical data were analysed on a per lesion basis, and the statistical test did not account for the correlation of multiple lesions within patients. Clinical data computations were performed using SPSS (IBM Corp., Armonk, NY, USA). The exact test used for each data set is mentioned in figure legends. * denotes P < 0.05, ** P < 0.01, *** P < 0.001. Extended methods are provided in Supplementary material online.

3. Results

3.1 Smoking increases the incidence of calcification in human atherosclerotic plaques

Smoking has been shown to correlate with higher incidence of vascular calcification. We assessed calcifications in 30 carotid artery atherosclerotic plaques of 15 smokers and compared to 32 plaques of 15 non-smokers using μCT scanning (Figure 1A and B). We divided the observed calcifications into three groups based on size and quantified their number and volume. Results show that, overall, calcification was present in 73.3% smokers and 34.4% non-smokers (P = 0.002, Table 1). Smoking was associated with a significantly higher prevalence of plaque calcifications of all size categories (microcalcifications were present in 21 lesions (70.0%) of smokers vs. eight lesions (25.0%) of non-smokers, P < 0.001; intermediate calcifications in 20 lesions (77.7%) vs. seven lesions (21.9%), P < 0.001; macrocalcifications in 18 lesions (60.0%) vs. four lesions (12.5%), P < 0.001; Table 1). Additionally, smokers had significantly more calcifications of all sizes (Figure 1C–E). The total volume of microcalcifications and intermediate calcifications, but not macrocalcifications, was also higher in smokers than in non-smokers (Figure 1F–H). These results suggest that smoking predisposes the formation of microcalcifications as well as calcification progression resulting in increased numbers of intermediate calcification and macrocalcification.

3.2 Nicotine increases VSMC calcification in vitro

To investigate the mechanisms underlying increased calcification observed with smoking, we investigated effects of nicotine, a major component of cigarette smoke, on human primary VSMC calcification in vitro. Nicotine increased calcification of VSMCs (Figure 2A), as well as other hallmarks of active mineralization processes. Expression of some osteogenic markers was increased: transcription factors Runx2 and Osf and downstream targets OCN, BSP, and OPN (Figure 2B–F); however, others did not show a consistent pattern of upregulation (Supplementary material online, Figure S1A–D). Increased osteogenic gene expression was accompanied by a decrease in expression of some contractile markers: SM22α mRNA (Figure 2G) and aSMA, CNN1, p-MLC on protein level (Figure 2H–K). Expression of other contractile markers did not show a consistent pattern of regulation (Supplementary material online, Figure S1E–I). We also examined expression of markers characteristic of the dedifferentiated (synthetic) phenotype (KLF4, S100A4) and found it not to be changed by nicotine (Supplementary material online, Figure S1J and K).

Califying EVs play an important role in the initiation and development of vascular calcification. We found that EV release was increased by nicotine (Figure 2L, Supplementary material online, Figure S1L), as was expression of EV-related genes (Figure 2M and N). Surprisingly, we observed that VSMCs treated with nicotine showed decreased proliferation rates compared to control (Supplementary material online, Figure S2A). Nicotine at the concentration and time point used for these assays did not affect VSMC viability at the time points the cells were collected for analysis (Supplementary material online, Figure S2B and C). Taken together, these results suggest dedifferentiation of VSMCs and activation of some calcification-promoting mechanisms as a result of exposure to nicotine.
3.3 Nicotine induces ROS production in VSMCs

As nicotine is a known inducer of oxidative stress and increased reactive oxygen species (ROS) are an important risk factor for atherosclerosis and calcification, we investigated the effect of nicotine on ROS production in VSMCs. We found that nicotine induced ROS production in VSMCs (Figure 3A). Further to that, nicotine-induced ROS and EV production could be blocked by antioxidant vitamin K2 (Figure 3B and C), and this leads to decreased calcification (Figure 3D). The same effect was observed for antioxidant N-acetylcysteine (NAC, Figure 3E). This suggests that the calcification-promoting effects of nicotine are mediated by increased ROS production.

3.4 Nox5 mediates pro-calcific effects of nicotine

To reveal the source of increased ROS, we examined the expression of p22phox, Nox1, Nox2, Nox4, and Nox5, enzymes implicated in oxidative stress in vascular disease. We confirmed that Nox2 is not...
expressed in aortic VSMCs (Supplementary material online, Figure S3A), and expression of Nox1 and Nox4 was not changed by nicotine treatment (Figure 4A, B, E, G). Interestingly, expression of p22phox was decreased by nicotine (Figure 4C), while expression of Nox5 was increased, however only at mRNA level and not protein (Figure 4D–F). To investigate this further, we used pan-Nox inhibitor GKT136901 and found that it significantly blocked nicotine-induced ROS production, suggesting a potential role for Nox enzymes in these processes (Figure 4H). Pan-Nox inhibitor GKT136901 was not sufficient to reduce nicotine-induced calcification (Figure 4I). Nox5 activity is known to be mediated by Ca\(^{2+}\) binding to this enzyme, and we have previously shown that increased intracellular Ca\(^{2+}\) mediates increased ROS production by Nox5. Therefore, we wanted to investigate whether nicotine induces changes in intracellular Ca\(^{2+}\). First, we showed that nicotine did induce an increase in intracellular Ca\(^{2+}\) (Figure 4J). Further to that, intracellular Ca\(^{2+}\) chelator BAPTA-AM attenuated nicotine-induced ROS production in VSMCs (Figure 4K). To confirm that this effect is mediated by Nox5, we performed siRNA knockdown of Nox5 (Figure 4L and M). Results show that Nox5 siRNA significantly lowered nicotine-induced ROS production (Figure 4N), EV release (Figure 4O), and calcification (Figure 4P). In order to examine the possible contribution of other Nox enzymes to nicotine-mediated calcification, we carried out p22phox siRNA knockdown and demonstrated that it did not induce a significant change in this process (Supplementary material online, Figure S3B and C).

In order to examine alternative mechanisms leading to oxidative stress-mediated calcification and phenotype changes of VSMCs, we investigated the SrcF/JAK-STAT3/ERK pathways (Supplementary material online, Figure S4A). While we observed a trend towards increased STAT3 phosphorylation (P = 0.051) after nicotine treatment (Supplementary material online, Figure S4B and C), inhibition of STAT3 phosphorylation with Stat3 did not consistently change EV release and calcification (Supplementary material online, Figure S4D–E). Additionally, inhibition of SrcF with SU6656 and ERK phosphorylation with GSK2656157 did not change nicotine-induced EV release or calcification (Supplementary material online, Figure S4D–E). Taken together, these results suggest that these pathways do not play a role in mediating nicotine-induced EV release and calcification.

### 3.5 Nicotine mediates its effects through interaction with α3 and α7 nicotinic acetylcholine receptors

Subsequently, we investigated which nicotinic acetylcholine receptor (nAChR) subunit mediates the effects of nicotine in VSMCs. We used two nAChR inhibitors, hexamethonium bromide and α-bungarotoxin, which inhibit α3 and α7-9 nAChR subunits, respectively.\(^{34,35}\) VSMCs do not express α8 and α9 subunits.\(^{36}\) Both hexamethonium bromide and α-bungarotoxin reduced nicotine-induced intracellular ROS production (Figure 5A). While hexamethonium bromide significantly decreased VSMC calcification, α-bungarotoxin did so only slightly (Figure 5B). However, α-bungarotoxin reduced nicotine-induced raise in intracellular Ca\(^{2+}\) (Figure 5C), but not EV release (Figure 5D) or expression of Nox5 and EV-related genes (Figure 5E–G). These data suggest that both α3 and α7 nAChR are involved in mediating effects of nicotine in VSMCs.

### Table 1 Characteristics of patients, whose lesions were used for the study

| Clinical data | Smoking n = 30 | Non-smoking n = 32 | P-value |
|---------------|---------------|-------------------|---------|
| Age (years)   | 74.5 ± 11.5   | 75.2 ± 10.4       | NS      |
| Male (n, %)   | 14 (46.7)     | 17 (53.1)         | NS      |
| Diabetes (n, %) | 14 (46.7)   | 14 (43.8)         | NS      |
| Glucose (mmol/L) | 8.8 ± 3.6  | 9.1 ± 3.4         | NS      |
| CRP (mg/L)    | 155.1 ± 149   | 113.4 ± 112.2     | NS      |
| Calcification (n, %) | 22 (73.3) | 11 (34.4)         | 0.002   |
| Overall NOC (n) | 921.5 ± 1305.5 | 543.3 ± 146.2 | 0.001   |
| Microcalcification |             |                   |         |
| Present (n, %) | 21 (70.0)    | 8 (25.0)          | <0.001  |
| NOC (n)       | 917.7 ± 1303.7 | 53.7 ± 145.8     | 0.001   |
| Volume (mm\(^2\)) | 0.180 ± 0.235 | 0.018 ± 0.045 | <0.001  |
| Total calcification (AU) | 207.8 ± 268.7 | 22.5 ± 55.3 | <0.001  |
| Intermediate size calcification |             |                   |         |
| Present (n, %) | 20 (66.7)    | 7 (21.9)          | <0.001  |
| NOC (n)       | 2.43 ± 2.40   | 0.38 ± 1.10       | <0.001  |
| Volume (mm\(^2\)) | 0.069 ± 0.068 | 0.011 ± 0.0034 | <0.001  |
| Total calcification (AU) | 89.55 ± 91.97 | 15.79 ± 45.59 | <0.001  |
| Macrocalcification |             |                   |         |
| Present (n, %) | 18 (60.0)    | 4 (12.5)          | <0.001  |
| NOC (n)       | 1.37 ± 1.38   | 0.31 ± 1.00       | 0.001   |
| Volume (mm\(^2\)) | 2.47 ± 4.07 | 1.28 ± 6.77       | NS      |
| Total calcification (AU) | 4610.8 ± 9766.4 | 2360.9 ± 12 654.4 | NS      |

The data are presented as mean ± SD or n (%). Data were analysed on a per lesion basis, and the statistical test did not account for the correlation of multiple lesions within patients. AU, arbitrary units; NOC, number of calcifications.
Figure 2  Nicotine increases VSMC calcification in vitro. (A) Calcification was induced with elevated Ca\(^{2+}\) concentrations (5.4 mM) in DMEM with 2.5% FBS in the presence of nicotine (1 mM, 5–7 days) and quantified using an o-cresolphthalein colorimetric assay. Cells were seeded in 48-well plates at 15 000 cells/well. Data from \(n = 9\) independent experiments. Statistical significance was tested with one-sample test. (B–F) qPCR analysis of osteogenic genes RUNX2, Oss, OCN, BSP, OPN, and (G) contractile marker SM22\(\alpha\) in VSMCs treated with nicotine (1 \(\mu\)M or 1 mM, 7 days in DMEM with 20% FBS). Statistical significance was tested with one-sample test. Data from \(n = 3\) (B, D), \(n = 5\) (C), \(n = 7\) (E), \(n = 4\) (F, G) independent experiments. In case of borderline significance, more samples were added to rule in/rule out the genes that are involved in nicotine-induced changes in VSMCs. (H–K) Western blotting and quantification of contractile markers \(\alpha\)SMA, CNN1, p-MLC in VSMCs treated with nicotine (1 mM, 7 days in DMEM with 20% FBS). Labels show protein standard (kDa). Data from \(n = 4\) (I, J) and \(n = 3\) (K) independent experiments. Statistical significance was tested with one-sample test. (L) VSMCs treated with nicotine (1 mM, 24 h) in DMEM with 0.5% FBS secrete more EVs than VSMCs treated with vehicle control. EVs were captured with anti-CD63-coupled beads, detected with a fluorescently labelled anti-CD81 antibody and quantified using flow cytometry. Cells were seeded in 48-well plates at 15 000 cells/well. Data from \(n = 3\) independent experiments in triplicate or quadruplicate. Statistical significance was tested with one-sample test. (M and N) qPCR analysis of EV-related genes; CD63 and SMPD3 mRNA expression treated with nicotine (1 mM, 7 days in DMEM with 20% FBS). Data from \(n = 12\) (M) and \(n = 8\) (N) independent experiments. Statistical significance was tested with one-sample test.
3.6 Nox5 expression correlates with the amount of calcification in human atherosclerotic plaques

Finally, to examine whether our findings have relevance in vivo, we examined expression of Nox5 as well as contractile marker CNN1, synthetic marker S100A4, and EV marker CD63 in human carotid arteries of 15 smokers and 15 non-smokers, whose arteries were previously examined by μCT (Figure 1). Immunohistochemistry showed markedly increased expression of Nox5 in smokers compared to non-smokers, while levels of CNN1, S100A4, and CD63 were not changed (Figure 6A–E). Interestingly, we found a positive correlation ($r = 0.8187, P < 0.0001$) between calcification (measured by μCT) and Nox5 expression (score) in both smokers and non-smokers (Figure 6E). Taken together, these data suggest that smoking is associated with increased Nox5 expression and that Nox5 promotes calcification in vivo.

4. Discussion

In this study, we demonstrated that smoking is associated with a significant increase in both micro- and macrocalcification in human carotid artery atherosclerotic plaques. We showed through in vitro studies that nicotine directly affects human VSMCs through α3 and α7 nAChR and induces all the major hallmarks of calcification. We uncovered a novel mechanism by which nicotine induces an increase in intracellular Ca$^{2+}$, resulting in Nox5-mediated intracellular oxidative stress providing the perfect storm for VSMC calcification (Figure 7).

4.1 Smoking is associated with vascular microcalcification and vulnerable plaque phenotype

We show that calcification is significantly more present in smokers than in non-smokers. Our data support previous studies which reported a
Figure 4 Nox5 mediates pro-calcific effects of nicotine. (A–D) qPCR analysis of NOX subunit mRNA expression in VSMCs treated with nicotine (1 mM, 7 days in DMEM with 20% FBS). Data from \( n = 3 \) independent experiments in single (A) and \( n = 4 \) independent experiments in duplicate or triplicate (B–D). Statistical significance was tested with t-test. (E–G) Western blotting and quantification of Nox4 and Nox5 protein in VSMCs treated with nicotine (1 mM, 7 days in DMEM with 20% FBS). Labels show protein standard (kDa). Data from \( n = 4 \) independent experiments in single or duplicate and \( n = 4 \) independent experiments in single or triplicate. Statistical significance was tested with t-test. (H) Pre-treatment of VSMCs with GKT136901 (1 \( \mu \)M, 1 h) prior nicotine stimulation (1 mM, 40 min, 8000 cells/well) reduces nicotine-induced intracellular ROS. Data from one experiment in quadruplicate, representative of three independent experiments. Statistical significance was tested with ANOVA. (I) VSMC calcification was induced with calcification medium (2.5% FBS, 3.6 mM Ca\(^{2+}\)) in the presence of nicotine (1 mM), with or without pre-treatment with GKT (1 \( \mu \)M, 1 h), for 3–5 days. Cells were seeded in 48-well plates at 15,000 cells/well. Calcification was detected using Fetuin A-Alexa-546. Data from four independent experiments, each in triplicate or quadruplicate. Statistical significance was tested with Kruskal–Wallis test. (J) Nicotine (10 mM, 5 min) induces an increase in intracellular Ca\(^{2+}\) (measured using Fluo-4-AM). Cells were seeded in 96-well plates at 8000 cells/well. Data from one experiment in quadruplicate, representative of three independent experiments. Statistical significance was tested with \( t \)-test. (K) Pre-treatment of VSMCs with BAPTA-AM (1 \( \mu \)M, 1 h) reduces nicotine-induced intracellular Ca\(^{2+}\) (10 mM nicotine, 5 min, 8000 cells/well). Data from one experiment in quadruplicate, representative of three independent experiments. Statistical significance was tested with ANOVA. (L–M) Western blot showing that siRNA knock-down (24 h) decreased Nox5 protein expression. Labels show protein standard (kDa). Data from \( n = 4 \) independent experiments in single or duplicate. Statistical significance was tested with one-sample test. (N) SiRNA knock-down of Nox5 (24 h) decreased VSMC intracellular ROS (data from one experiment in triplicate, representative of three independent experiments), (O) EV secretion (data from one experiment in triplicate, representative of three independent experiments), and (P) VSMC calcification (2.5% FBS, 3.6 mM Ca\(^{2+}\), 3–5 days). Data from one experiment in quadruplicate, representative of three independent experiments. Statistical significance was tested with ANOVA (N–P).
significant association between smoking and coronary artery as well as aortic calcification. While smoking has recently been shown to be an independent risk factor for carotid artery plaque calcification, 39 calcifications have not been analysed with respect to their size. It has been shown that microcalcifications affect atherosclerotic plaque stability. 40 We extend the current knowledge and show that smoking is...
associated with 17-fold increase in microcalcifications within atherosclerotic lesions. Since microcalcifications are biologically active and are an important feature of vulnerable plaques, our data suggest that smoking may be associated with a more vulnerable plaque phenotype. Indeed, studies have shown that cigarette smoke impacts the composition of the plaque, which contributes to plaque vulnerability and increased risk of plaque rupture.

### 4.2 Nicotine induces phenotypic switching of VSMCs and initiates calcification

In this study, we elucidate the mechanism by which nicotine initiates vascular calcification in VSMCs. First, we show that nicotine downregulates VSMC contractile markers (SM22α, αSMA, CNN1, and p-MLC) and upregulates bone-specific markers (Runx2, Osx, OCN, BSP, and OPN). This is in line with previous studies showing that nicotine decreased

---

*Figure 6* Smoking and calcification are associated with increased carotid artery Nox5 expression. (A) Immunohistochemical analysis of Nox5, CNN, and S100A4 expression in carotid artery samples from human donors. I and M indicate intima and media, respectively. Scale bars are 250 μm. Figure shows representative images from 32 carotid artery samples that were stained (15 smokers, 15 non-smokers). (B–D) Quantification of protein expression scores. Statistical significance was tested with Mann–Whitney U-test. Dots denote individual data points. Graphs (B–D) show n ≥ 15 plaques for smokers, n ≥ 15 plaques for non-smokers. (E) Nox5 expression positively correlates with calcification (P < 0.001, r = 0.8187 and P < 0.0001, r = 0.794, when outliers are removed). Nox5 expression scores were plotted against μCT total calcification scores for each patient. Graph shows individual data points (both smokers and non-smokers). Linear regression was plotted, and a two-tailed Pearson correlation test was carried out. Graph shows n = 14 plaques.
expression of αSMA, SM22α, and increased expression of OPN in murine VSMCs and OPN and inflammatory cytokines in human VSMCs. Another study reported that nicotine differentiated VSMCs to a synthetic phenotype, demonstrated by a reduction in SM22α and h-caldesmon, and increased in myosin-II and β-actin gene expression. Unexpectedly, the observed decrease in contractile markers in our experiments was not accompanied by a nicotine-induced increase in synthetic phenotype markers. This could be explained by the heterogeneity of VSMCs and sub-clonal population of VSMCs, which do not uniformly express specific markers at specific time points. More recent understanding points to the notion that VSMCs exhibit co-expression of genes rather than a two-end spectrum, contractile and synthetic phenotype, and that intrinsic and extrinsic factors as well as the developmental phase of the aorta should be taken into account.

Phenotypic switching of VSMCs can be caused by various stimuli, including oxidized cholesterol, inflammatory cytokines, PDGF, and oxidative stress. We found that nicotine mainly acts via increasing oxidative stress, as it markedly induced intracellular ROS production and ROS-mediated nicotine-induced calcification. It is well documented that nicotine induces ROS generation both in animal studies and in murine and rat VSMCs (as cigarette smoke extract). However, our study is the first to show a causative link between ROS, nicotine, and VSMC calcification.

We also show that ROS production induced by nicotine leads to increased EV release from VSMCs. Both quantification using a CD63/CD81 bead capture assay and NTA suggest a role for exosomes; however, we cannot exclude a role for larger microvesicles, which were also present in VSMC culture supernatants. EVs are a well-known inducer of calcification, and it is known that phenotypic switching of VSMCs results in increased secretion of EVs. Pathological conditions induce release of EVs with distinct composition, which may affect cellular phenotypes. Indeed, release of EVs from osteogenic VSMCs promotes mineralization. Nicotine (as cigarette smoke extract) has been shown to affect the composition of EVs in lung cancer and bronchial epithelial cells, and higher levels of local site EVs were found in lungs of smokers. Interestingly, nicotine reduced monocyte-derived EV release. However, to our knowledge, there is no previous data on the effect of nicotine on EV release from VSMCs.

4.3 nAchR and Nox5 mediate pro-calcific processes induced by nicotine

We investigated the intracellular source of increased ROS, and, through pharmacological inhibition and knockdown experiments, we identified Nox5 as a key regulator of nicotine-induced ROS generation and calcification in human VSMCs. Nox enzymes are a major source of ROS in vascular diseases; however, the mechanism linking nicotine and oxidative stress in VSMCs is not well described in the literature. The effect of cigarette smoke on inducing vascular Nox activity has mainly been studied in endothelial cells and in rabbit VSMCs suggest the involvement of Nox2 after nicotine induction. In our experiments, nicotine did not significantly change Nox1 or Nox4 expression, but decreased p22phox expression. However, Nox5 mRNA was increased by nicotine, and despite the lack of increased Nox5 protein expression in our study, we found that siRNA knock-down of Nox5, but not p22phox (the subunit required for Nox1, Nox2, and Nox4 activity), attenuated nicotine-induced ROS production, EV release, and calcification. This indicates that although Nox5 levels are not altered, activity of Nox5 is increased. Nox5 is a unique Nox, as it does not require other subunits for activity, but does require Ca²⁺ binding. We found that nicotine significantly raises intracellular Ca²⁺ within VSMCs, thereby contributing to increased Nox5 activity without increasing Nox5 expression. Our data are in line with a previous study showing that nicotine increases intracellular Ca²⁺ levels in human VSMCs.
We also investigated an alternative mechanism leading to oxidative stress-mediated phenotypic switching of VSMCs and calcification, involving Janus kinase (JAK)/Signal transducers and activator of transcription (STAT) signalling, a critical pathway that regulates cell proliferation, differentiation, and apoptosis.\textsuperscript{70} Our data show that nicotine induces STAT3 phosphorylation in VSMCs. However, inhibiting STAT3, SrcFK, and ERK phosphorylation did not reduce nicotine-induced EV release and calcification, which was consistent with decreased proliferation rate of VSMCs treated with nicotine. This data merits caution as in vitro experimental time-points models more accurately interpret acute smoking than habitual smoking, which might involve activation of different signaling pathways.\textsuperscript{71} The STAT3/SrcFK pathway was shown to be only activated during 24-h nicotine exposure of rat VSMCs but not after 48-h nicotine exposure.\textsuperscript{71} The fact that we did not see nicotine-induced changes in EV release and VSMC calcification when inhibiting STAT3 after 7 days of treatment might be explained by a transient involvement of STAT3 phosphorylation at only the initial exposure to nicotine. As a result of this, STAT3 might not necessarily participate in the mechanisms of EV release and calcification of VSMCs. In line with our results, cholesteryl ester-transfer protein inhibitor treatment of rat VSMCs showed that STAT3 phosphorylation was unaffected by oxidative stress inhibitor NAC and Nox inhibitor GKT137831, suggesting that these two pathways are independent from each other.\textsuperscript{72} With the data obtained in our study, we conclude that nicotine-mediated VMSC calcification does not depend on SrcFK/JAK-STAT3/ERK pathways.

In this study, we show that nicotine affects VSMCs at least in part through binding of \( \alpha_3 \) and \( \alpha_7 \) nAChR. We show that inhibition of \( \alpha_3 \) and \( \alpha_7 \) nACHR results in decreased intracellular ROS. Inhibition of \( \alpha_3 \) nAChR reduces nicotine-induced VMSC calcification whereas inhibition of \( \alpha_7 \) nAChR reduces nicotine-induced intracellular Ca\(^{2+}\). Indeed, others have shown that nicotine increases intracellular Ca\(^{2+}\) of rat airway smooth muscle cells through \( \alpha_7 \) nAChR.\textsuperscript{73} However, the connection between \( \alpha_7 \) nAChR and Nox5-mediated oxidative stress in VSMCs has not been made before. Although a previous study has shown that \( \alpha_7 \) nAChR is the most abundantly expressed subunit in human VSMCs,\textsuperscript{74} we did not observe a significant reduction of nicotine-induced EV secretion when inhibiting \( \alpha_7 \) nAChR. Therefore, we conclude that other nAChRs may also play roles in VMSC phenotypic switching.

To confirm our in vitro findings, we show that carotid arteries of patients who smoked have higher Nox5 expression levels than arteries of non-smokers. Because we did not observe Nox5 expression consistently elevated in nicotine-induced VSMCs, the elevated expression in carotid arteries could be attributed to the length and amount of cigarette that smokers were exposed to, or other chemical constituents in the cigarette which also induce oxidative stress via Nox activity.\textsuperscript{75} More interestingly, Nox5 expression positively correlates with degree of calcification in these patients. Specifically, the correlation of Nox5 and calcification is the strongest at lower scores of calcifications. This observation may imply an involvement of Nox5 in initiating calcification after being induced by nicotine. Once calcification is present, it induces more changes in the vasculature that lead to more calcification.\textsuperscript{76–78} While the presence of Nox5 in the atherosclerotic plaques of human carotid arteries is known,\textsuperscript{80–82} a direct association between smoking and Nox5 expression has not been described. Amongst vascular diseases, smoking is known as one of the strongest life-style risk factors for development and calcification of abdominal aortic aneurysm (AAA).\textsuperscript{83–86} Interestingly, Nox5 expression was significantly increased in aortic aneurysm segments compared to matched non-dilated aortic specimens.\textsuperscript{87} Additionally, increased oxidative stress was significantly associated with smoking in the aortic aneurysm segments.\textsuperscript{87} Our in vivo data put forward Nox5 as a key mediator of vascular calcification caused by smoking.

### 4.4 Vitamin K ameliorates effects of nicotine on VSMCs

Given the role of oxidative stress in the pathogenesis of vascular calcification, antioxidant therapy may represent a viable therapeutic approach. We found that pre-treatment of VSMCs with vitamin K attenuates nicotine-induced intracellular ROS generation, reduces EV release, and subsequently inhibits calcification. However, we have not excluded that vitamin K could decrease calcification by its direct effect on \( \gamma \)-glutamylcarboxylation. Vitamin K is involved in multiple cellular processes and has important implications in cardiovascular and bone diseases.\textsuperscript{88} The primary role of vitamin K is to serve as a cofactor in the activation of coagulations factors and vitamin K-dependent calcification inhibitors such as matrix Gla-protein.\textsuperscript{89} However, vitamin K also exerts antioxidative properties, as several studies have demonstrated.\textsuperscript{90–94} It has also been shown that vitamin K can serve as an electron donor for the plasma membrane Nox of soya bean plant, which may implicate protection of plasma membranes against ROS.\textsuperscript{95} Nicotine administration in rats fed with a high-fat diet was shown to lower scavenging activity of antioxidant enzymes.\textsuperscript{96} It is therefore tempting to speculate that vitamin K may be a useful agent to counteract the development of nicotine-induced vascular pathologies.

Taken together, we propose a novel mechanism by which nicotine induces VMSC calcification, via a sequence of events involving a raise in intracellular Ca\(^{2+}\) via the \( \alpha_7 \) nAChR, increasing ROS production by \( \alpha_2\beta_3 \)–independent Nox5 and increasing EV release. We show that smoking is associated with increased vascular microcalcification in atherosclerotic plaques and that both smoking and degree of calcification correlated with increased Nox5 expression. Finally, we show that reducing oxidative stress using vitamin K ameliorates effects of nicotine on VSMCs. Nicotine is the primary agent in both cigarettes and e-cigarettes. Our findings add to the current literatures that vaping may not be a healthier choice when it comes to vascular health. Our study contributes to the understanding of how nicotine not only affects atherosclerotic plaque calcification but possibly also other VMSC-mediated vascular diseases, such as hypertension\textsuperscript{97,98} and aortic aneurysm.\textsuperscript{99,100}

### 4.5 Limitations of the study

(i) Detailed characterization of the study cohort is not available. We have included all parameters we were able to access, but did not have information about further patient characteristics such as cardiovascular risk factors (e.g. family history, hypertension), laboratory values (LDL, HDL, cholesterol, triglycerides, hsCRP), and medication. (ii) The discrepancy between VMSC markers in vitro and in vivo observations could be attributed to the length and amount of cigarette that smokers were exposed to. In vivo data from vascular tissue of a smoker represent years of cigarette exposure, and possibly vascular repair and remodelling as compensation. In vitro data represent direct effect of nicotine and the immediate consequences that lead to VMSC pathology. We did not observe differences in S100A4 expression both on mRNA level in vitro and by immunohistochemistry in vivo. This is consistent with previous findings that S100A4, while associated with VMSC phenotype in certain conditions,\textsuperscript{101} does not increase with increased Nox5 activity. The tissue analysed by immunohistochemistry might represent various stages of atherosclerosis and various locations in the plaque, which we could not control for. It is possible that active synthetic differentiation occurs only
at certain stages and locations of the vessel and thus any differences in expression are obscured, even though they may have been present. Additionally, the lack of correlation of S100A4 with Nox5 expression confirms our previous findings that overexpression of Nox5 or H2O2-induced oxidative stress downregulates expression of S100A4 in VSMCs. Therefore, we cannot unequivocally conclude the nature of S100A4 regulation because of the interaction between nicotine treatment and oxidative stress. Further to that, we saw no difference in CNN1 expression in smokers vs. non-smokers by immunohistochemistry, which could be attributed to similar reasons. (iii) We have not investigated the involvement of other members of the Nox family in mediating nicotine-induced effects on VSMCs. However, we have previously investigated the involvement of Nox1 and Nox4 in VSMC differentiation and calcification and found that they were not involved.34 While literature shows that Nox2 is involved in mediating oxidative stress in VSMCs,102,103 it has not been examined whether this leads to increased calcification.

Supplementary material
Supplementary material is available at Cardiovascular Research online.

Authors’ contributions
PP, MB, BW, NS, SH, and MF performed the experiments and analysed the data; PP, MB, MF, and LS wrote the manuscript; PP, MB, BW, BM, MF, and LS designed the study; FG, SR, KB, FK, NM, EN, EB, MJ, CR, BM, MF, and LS provided patient material and discussed the study; PP, MB, MF, and LS edited the manuscript, and all authors approved the final manuscript; PP and MB contributed equally to this work.

Acknowledgements
The authors would like to thank Cecile Maassen and Peter Leenders for excellent technical support.

Conflict of interest: L.S. is an unpaid consultant to immunodiagnostic systems (IDFs) and receives research grants from Nattopharma, Bayer, Boehringer Ingelheim, and Daiichi Sankyo. F.G. is the owner of Gremse-IT GmbH.

Funding
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 675111 and 722609. This study was partly funded by NWO ZonMW (MKMD 40-42600-98-13007) grant to C.R. and L.S.

Data availability
All data are incorporated into the article and its Supplementary material online.

References
1. CDC / U.S. Department of health and human services. Surgeon General’s Report: The Health Consequences of Smoking—30 Years of Progress 2014;8:458-512.
2. White WB. Smoking-related morbidity and mortality in the cardiovascular setting. Prev Cardiol 2007;10:1-4.
3. Willett WC, Green A, Stampfer MJ, Speizer FE, Colditz GA, Rosner B, Monson RR, Stason W, Hennekens CH. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med 1987;317:1303-1309.
4. McEvoy JW, Blaha MJ, Dellipassop N, Lima JAC, Blumenthal RS, Min JK, Lloyd-Jones DM, Graham Barr R, Budoff MJ, Blumenthal RS, Nasir K. Cigarette smoking and cardiovascular events: role of inflammation and subclinical atherosclerosis from the multietnic study of atherosclerosis. Arterioscler Thromb Vasc Biol 2015;35:700–709.
5. Wang Y, Osborne MT, Tung B, Li M, Li Y. Imaging cardiovascular calcification. J Am Heart Assoc 2018;7:e008564.
6. Kelly-Arnold A, Maldonado N, Lauter D, Aikawa E, Cardoso L, Weinbaum S. Revised microcalcification hypothesis for fibrous cap rupture in human coronary arteries. Proc Natl Acad Sci USA 2013;110:10741–10746.
7. Shioi A, Ikarı Y. Plaque calcification during atherosclerosis progression and regression. J Atheroscler Thromb 2018;25:294–303.
8. Chatrou MILL, Cleutjens JP, Vusse JG, van der Roijers RB, Mutsaers PHA, Schulgers LJ. Intra-section analysis of human coronary arteries reveals a potential role for micro-calculifications in macrophage recruitment in the early stage of atherosclerosis. PLoS One 2015;10:e0142335.
9. Hutcheson JD, Maldonado N, Aikawa E. Small entities with large impact: microcalcifications and atherosclerotic plaque vulnerability. Curr Opin Lipidol 2014;25:327–332.
10. Nicolli R, Henein M. Arterial calcification: a new perspective? Int J Cardiol 2017;228:11–22.
11. Forsythe RO, Dweck MR, McBride OMB, Vesy AT, Simel SI, Shah ASV, Adamson PD, Wallace WA, Kaczynski J, Ho W, Beek EJJ, van Gray CD, Fletcher A, Lucatelli C, Marin A, Bums P, Tambara Y, Chalmers RTA, Weir G, Mitchell N, Tavasri A, Robinson JMR, Newby DE. 18–f–sodium fluoride uptake in abdominal aortic aneurysms. J Am Coll Cardiol 2018;71:513–523.
12. Durham AL, Speer MY, Scatena M, Giachelli CM, Shananan CM. Role of smooth muscle cells in vascular calcification: implications in atherosclerosis and arterial stiffness. Cardiovasc Res 2018;114:590–600.
13. Cecchettini A, Rocchiocchi S, Boccardi C, Citti L. Vascular smooth-muscle-cell activation: proteomics point of view. Int Rev Cell Mol Biol 2011;288:43–99.
14. Kapustin AN, Shananan CM. Calcium regulation of vascular smooth muscle cell-derived matrix vesicles. Trends Cardiovasc Med 2012;22:133–137.
15. Kapustin AN, Shananan CM. Emerging roles for vascular smooth muscle cell exosomes in calcification and coagulation. J Physiol 2016;594:2905–2914.
16. Byon CH, Javed A, Dai Q, Kappes JC, Clemens TL, Darley-Usmar VM, McDonald JM, Chen Y. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling. J Biol Chem 2008;283:15319–15327.
17. Liu M, Gomez D. Smooth muscle cell phenotypic diversity. Arterioscler Thromb Vasc Biol 2019;39:1715–1723.
18. Basatemur GL, Jørgensen HF, Clarke MCH, Bennett MR, Mallat Z. Vascular smooth-muscle cells in atherosclerosis. Nat Rev Cardiol 2019;16:727–718.
19. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001;104:365–372.
20. Hisamatsu T, Miura K, Arima H, Kadota A, Kadowaki S, Torii S, Suzuki S, Miyagawa N, Sato A, Yamazoe M, Ueshima H. Smoking, smoking cessation, and measures of subclinical atherosclerosis in multiple vascular beds in Japanese men. J Am Heart Assoc 2016;5:e003738.
21. McEvoy JW, Nasir K, Dellipassop N, Lima JAC, Bluemke DA, Hundley WG, Barr RG, Budoff MJ, Sildoo M, Navas-Acien A, Polak JF, Blumenthal RS, Post WS, Blaha MJ, Relationship of cigarette smoking with inflammation and subclinical vascular disease: the multi-ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol 2015;35:1002–1010.
22. Kromal RA, McClelland RL, Detrano R, Shea S, Lima JA, Cushman M, Bild DE, Burke GL. Risk factors for the progression of coronary artery calcification in asymptomatic subjects: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 2007;115:2722–2730.
23. Rasmussen T, Frestad D, Kober L, Pedersen JH, Thomsen LH, Dirksen A, Kofoed KF. Development and progression of coronary artery calcification in long-term smokers: adverse effects of continued smoking. J Am Coll Cardiol 2013;62:255–257.
24. Benowtiz NL, Burbank AD. Cardiovascular toxicity of nicotine: implications for electronic cigarette use. Trends Cardiovasc Med 2016;26:515–523.
25. Babic M, Schuchardt M, Tölle M, van der G. In times of tobacco-free nicotine consumption: the influence of nicotine on vascular calcification. Eur J Clin Invest 2019;49:e13077.
26. Stadler N, Heeneman S, Vöö S, Stanley N, Giles GI, Gang BP, Croft KD, Mori TA, Vacca V, Daemen MJAP, Wellenberger J, Davies MJ. Reduced metal ion concentrations in atherosclerotic plaques from subjects with Type 2 diabetes mellitus. Atherosclerosis 2012;222:512–518.
27. Gremse F, Mähring A, Möslin JA, Menngen J, ten Brinke H, Kießling F. Imalytics. Proteomics point of view. J Proteomics 2018;178:141–146.
Nicotine- and Nox5-mediated pro-calcific processes

24. Bahkhan Nik A, Hutchinson JD, Aikawa E. Extracellular vesicles as mediators of cardiovascular calcification. Front Cardiovasc Med 2017;4:78.

25. Khademian F, Tobotchi H, Mohammadi N, Zare R, Zai F. Nicotine-induced oxidative stress in human primary endometrial cells. Int J Toxicol 2019;38:202–208.

26. Barr J, Sharma CS, Sarker S, Wise K, Dong L, Periyakaruppan A, Ramesh GT. Nicotine induces oxidative stress and activates nuclear transcription factor kappa B in rat mesenchymal cells. Mol Cell Biochem 2007;297:93–99.

27. Liu C-C, Yeh H-H. Nicotine: a double-edged sword in atherosclerotic disease. Acta Cardiol Sin 2014;30:108–113.

28. Sirker A, Zhang M, Shah AM. NADPH oxidases in cardiovascular disease: insights from in vivo models and clinical studies. Basic Res Cardiol 2011;106:735–747.

29. Furmanik M, Chatrou M, van Gorp R, Akbulut A, Willems B, Schmidt H, van Eys G. Receptor tyrosine kinases and extracellular vesicle-mediated vascular calcification. Grc 2020;207:911–927.

30. Colquhoun LM, Patrick JW. Pharmacology of Neuronal Nicotinic Acetylcholine Receptor Subtypes. Adv Pharmacol 1999;37:191–220.

31. Barr J, Sharma CS, Sarkar S, Wise K, Dong L, Periyakaruppan A, Ramesh GT. Nicotine-induced oxidative stress in human primary endometrial cells. Mol Cell Biochem 2007;297:93–99.

32. Fujita Y, Araya J, Ito S, Kobayashi K, Kasaka N, Yoshikoa Y, Kadota T, Hara H, Kuvano K, Ochiya T. Suppression of autophagy by extracellular vesicles promotes myofibroblast differentiation in COPD pathogenesis. J Extrcell Vesicles 2015;4:2838.

33. Xu X, Hua Y, Wang L, Hou W, Xu M. Correlation between risk factors of cerebral vascular disease and calcified plaque patterns in patients with atherosclerotic severe carotid stenosis. Neurol Res 2020;42:83–89.

34. Furmanik M, Chatrou M, van Gorp R, Akbulut A, Willems B, Schmidt H, van Eys G. Receptor tyrosine kinases and extracellular vesicle-mediated vascular calcification. Grc 2020;207:911–927.

35. Colquhoun LM, Patrick JW. Pharmacology of Neuronal Nicotinic Acetylcholine Receptor Subtypes. Adv Pharmacol 1999;37:191–220.

36. Nelson ME, Lindstrom J. Single channel properties of human

37. Nelson ME, Lindstrom J. Single channel properties of human

38. Jia H, Abtahian F, Aguirre AD, Lee S, Chia S, Lowe H, Kato K, Yonetsu T, Vergallo NY. Smoking and inflammation in hemodialysis patients. J Biomol Sci 2004;27:53638–53690.

39. Yun YS, Choi SJ, Lee JY, Kim YS, Yoon SA, Park SC, Shin OR, Jang EJ, Kim YO. Impact of arterial microcalcification of the vascular access on cardiovascular mortality in hemodialysis patients. Hemodial Int 2014;18:54–61.

40. Jiang Y, Dai A, Zhou Y, Peng G, Hu G, Sham JSK, Ran P. Nicotine elevated intracellular Ca2þ concentrations in cavernosal vascular smooth muscle cells: mediation by superoxide. J Biol Chem 2016;291:34288.

41. Steffen Y, Vuillame G, Stolle K, Roewer K, Liete M, Schuele J, Lebrun S, Wallerath T. Cigarette smoke and LDL correlate in reducing nitric oxide bioavailability in endothelial cells via effects on both eNOS and NADPH oxidase. Nitric Oxide 2012;27:176–184.

42. Marques P, Collado A, Escudero P, Rius C, Gonzalez C, Servera E, Piqueras L, Sanz MJ. Cigarette smoke induces endothelial CXCL16-leukocyte CXCR6 adhesion in vitro and in vivo: some potential clinical consequences in chronic obstructive pulmonary disease. Front Immunol 2017;8:176.

43. Sage AP, Lu J, Tintut Y, Demer LL. Hyperphosphatemia-induced nanocrystals upregulate the bone morphogenetic protein-2 and osteopontin genes in vascular smooth muscle cells. J Cell Physiol 2017;232:389–401.

44. Wada T, Naito M, Kenmochi H, Tsuneki H, Sasaoka T. Chronic nicotine exposure regulates the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro. Atherosclerosis—Yesterday, Today and Tomorrow. IntechOpen 2018;47. doi:10.5772/intechopen.77010.
nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxida-
tive stress in human coronary artery disease. J Am Coll Cardiol 2008;52:1803–1809.
81. Manea A, Manea SA, Gan AM, Constantin A, Fenyo IM, Raiu M, Muresan H, Simionescu M. Human monocytes and macrophages express NADPH oxidase 5: a potential source of reactive oxygen species in atherosclerosis. Biochem Biophys Res Commun 2015;461:172–179.
82. Vlad ML, Manea S-A, Lazar A-G, Raiu M, Muresan H, Simionescu M, Manea A. Histone acetyltransferase-dependent pathways mediate upregulation of NADPH oxidase 5 in human macrophages under inflammatory conditions: a potential mech-
amism of reactive oxygen species overproduction in atherosclerosis. Oxid Med Cell Longev 2019;2019:3201062.
83. Kent KC, Zvolak RM, Egorova NN, Riles TS, Manganaro A, Moskowitz AJ, Gelijns AC, Greco G. Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals. J Vasc Surg 2010;52:539–548.
84. Norman PE, Curtis JA. Understanding the effects of tobacco smoke on the patho-
genesis of aortic aneurysm. Arterioscler Thromb Vasc Biol 2013;33:1473–1477.
85. Aune D, Schlesinger S, Norat T, Riboli E. Tobacco smoking and the risk of abdomi-
nal aortic aneurysm: a systematic review and meta-analysis of prospective studies. Scand J Respir 2018;8:14786.
86. Jung JG, Wu LT, Kim JS, Kim E, Du, Yoon SJ. Relationship between smoking and ab-
dominal aortic calcification on computed tomography. Korean J Fam Med 2019;40: 248–253.
87. Guzik B, Sagan A, Ludew D, Mrowiecki W, Chwała M, Bujak-Gizycka B, Filip G, Grudzien G, Kapelak B, Zmudka K, Mrowiecki T, Sadowski J, Korbut R, Guzik TJ. Mechanisms of oxidative stress in human aortic aneurysms—association with clinical risk factors for atherosclerosis and disease severity. Int J Cardiol 2013;168: 2389–2396.
88. Halder M, Petsophonsakul P, Abulut DJ, Pavlic A, Bohan F, Anderson E, Marez K, Kramann R, Schurgers L. Vitamin K: double bonds beyond coagulation insights into differences between vitamin K1 and K2 in health and disease. J Mol Med 2019;20:896.
89. Schurgers LJ, Utrio J. Reutelingsperger CP. Vitamin K-dependent carboxylation of matrix Glα-protein: a crucial switch to control ectopic mineralization. Trends Mol Med 2013;19:217–226.
90. Muki A, Morimoto H, Kikuchi S, Nagaoa S. Kinetic study of free-radical-scavenging action of biological hydroquinones (reduced forms of ubiquinone, vitamin K and to-
copherol quinone) in solution. Biochim Biophys Acta—Gen Subj 1993;1157:313–317.
91. Vervoort LH, Ronden JE, Thijssen HH. The potent antioxidant activity of the vita-
minal K cycle in microsomal lipid peroxidation. Biochem Pharmacol 1997;54:871–876.
92. Li J, Lin JC, Wang H, Peterson J, Wolfie BC, Furie B, Booth SL, Volpe JJ, Rosenberg PA. Novel role of vitamin K in preventing oxidative injury to developing oligoden-
drocytes and neurons. J Neurosci 2003;23:5816–5826.
93. Li J, Wang H, Rosenberg PA. Vitamin K prevents oxidative cell death by inhibiting activation of 12-15 lipoxynegenase in developing oligodendrocytes. J Neurosci Res 2009; 97:1997–2005.
94. Dai L, Schurgers LJ, Shiels PG, Stenwick P. Early vascular ageing in chronic kidney disease: impact of inflammation, vitamin K, senescence and genomic damage. Nephrol Dial Transplant 2020;35:i31–i37.
95. Bridge A, Barr R, Morré DJ. The plasma membrane NADH oxidase of soybean has vitamin K(1) hydroquinone oxidase activity. Biochem Biophys Acta 2000;1463: 448–458.
96. Ashkumary L, Vijayamalai PL. Effect of nicotine on antioxidant defence mechanisms in rats fed a high-fat diet. Pharmacology 1996;52:153–158.
97. Touyz RM, Alves-Lopes R, Rios FJ, Camargo LL, Anagnostopoulou A, Armer A, Montezano AC. Vascular smooth muscle contraction in hypertension. Cardiowasc Res 2018;114:529–539.
98. Jamison A, Reesink K, Kroon A, Schurgers L. The role of vascular smooth muscle cells in arterial remodeling: focus on calcification-related processes. J Mol Med 2019;20: 5694.
99. Kuivaniemi H, Ryer EJ, Elmore JR, Tromp G. Understanding the pathogenesis of ab-
dominal aortic aneurysms. Expert Rev Cardiovasc Ther 2015;13:975–987.
100. Petsophonsakul P, Furmanik M, Forsythe R, Dweck M, Schurink GW, Natour E, Reutelingsperger C, Jacobs M, Mees B, Schurgers L. Role of vascular smooth muscle cell phenotypic switching and calcification in aortic aneurysm formation. Arterioscler Thromb Vasc Biol 2019;39:1351–1368.
101. Chaabane C, Heizmann CW, Bochaton-Piallat ML. Extracellular S100A4 induces smooth muscle cell phenotypic transition mediated by RAGE. Biochim Biophys Acta 2015;1853:2144–2157.
102. Koniar A, Schramm A, Czesnikiewicz-Guzik M, Guzik T. NADPH oxidases in vas-
cular pathology. Antioxid Redox Signal 2014;20:2794–2814.
103. Bronies AM, Tabet F, Callera GE, Montezano AC, Yagi A, He Y, Quin MT, Salaces M, Touyz RM. Differential regulation of Nox1, Nox2 and Nox4 in vascular smooth muscle cells from WKY and SHR. J Am Soc Hypertens 2015;9:137–135.
104. Chomczynski P, Sacchi N. The single-step method of RNA isolation by acid guanidi-
num thiocyanate-phenol-chloroform extraction: twenty–something years on. Nucleic Acids Res 2000;26:1581–1585.
105. Reynolds JL, Joannides AJ, Slepper JN, McNair R, Schurgers LJ, Proudfoot D, Jahnen-
Dechent W, Weissberg PL, Shanahan CM. Human vascular smooth muscle cells un-
dergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calci-
fication in ESRD. J Am Soc Nephrol 2004;15:2857–2867.
106. Kapustin AN, Chatrou ML, Drozdov I, Zheng Y, Davidson SM, Soong D, Furmanik M, Sancho P, Rosales RTM, De Alarvez-Hernandez D, Shroff R, Yin X, Muller K, Slepper JN, Mayr M, Reutelingsperger CP, Chester A, Bertazzo S, Schurgers LJ, Shanahan CM. Vascular smooth muscle cell calcification is mediated by regulated exosome secretion. Circ Res 2015;116:1312–1323.
107. Jahnen-Dechent W, Heiss A, Schäfer C, Ketteler M. Fetuin-A regulation of calcified matrix metabolism. Towler DA, ed. Circ Res 2011;108:1494–1509.
108. Price PA, Lim JE. The inhibition of calcium phosphate precipitation by fetuin is ac-
companied by the formation of a fetuin-mineral complex. J Biol Chem 2003;278: 22144–22152.
109. Schinke T, Amendt C, Trindl A, Pöschke O, Müller-Esterl W, Jahnen-Dechent W. The serum protein α2-H glycophorin/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeo-
stasis. J Biol Chem 1996;271:20789–20797.
110. Rochette CN, Rosenfeld S, Heiss A, Narayan T, Ballauf M, Jahnen-Dechent W. A shielding topology stabilizes the early stage protein-mineral complexes of Fetuin-
A and calcium phosphate: a time-resolved small-angle X-ray study. ChemBiochem 2009;10:735–740.
111. Smith ER, Ford ML, Tolmimlin LA, Rajkumar C, Memahon LP, Holt SG. Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD. Nephrol Dial Transplant 2012;27:1957–1966.
112. Smith ER, Hewittson TD, Cai MMX, Aghagolzadeh P, Bachtler M, Pasch A, Holt SG. A novel fluorescent probe-based flow cytometric assay for mineral-containing nano-
particles in serum. Sci Rep 2017;7:17.
113. Giteles HJ. An improved automated procedure for the determination of calcium in biological specimens. Anal Biochem 1967;18:521–531.
114. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apo-
tosis Flow cytometric detection of phosphatidylserine expression on early apop-
totic cells using fluorescein labelled Annexin V. J Immunol Methods 1995;184:39–51.